BioVie (BIVI) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Lantern Pharma (LTRN) over the past year, losing 28.7% versus a loss of 82.4%. Over five years, LTRN leads with a -91.9% price change compared with -99.8% for BIVI. Lantern Pharma is the larger company by market cap ($12.1 million vs $12.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | LTRN |
|---|---|---|
| Share price | $1.39 | $0.8127 |
| Market cap | $12.07M | $12.14M |
| 1-day change | +8.59% | -2.08% |
| YTD return | +19.83% | -73.18% |
| 1-year return | -28.72% | -82.41% |
| 5-year return | -99.76% | -91.88% |
| EPS (TTM) | $-3.31 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $4.58 |
| 52-week low | $0.82 | $0.7603 |
| Distance from 52-week high | -63.32% | -82.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +278.42% | +2053.32% |
| Average volume | 4.67M | 180.50K |
| Shares outstanding | 8.68M | 14.94M |
| Employees | 13 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed LTRN by 53.7 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
BIVI vs LTRN FAQ
Which is bigger, BioVie or Lantern Pharma?
Lantern Pharma (LTRN) is larger, with a market capitalization of $12.14M compared with $12.07M for BioVie (BIVI).
Which stock has performed better over the past year, BIVI or LTRN?
BIVI returned -28.72% over the past 12 months, compared with -82.41% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.